Piramal Pharma Solutions, a CDMO and part of Piramal Pharma Ltd., announced a $90 million investment plan to expand two of its U.S. facilities. This investment underscores the company’s commitment to industry leadership through continuous growth and innovation.

Piramal Pharma Solutions is expanding its Riverview, Michigan, and Lexington, Kentucky, facilities. 

The Riverview site provides drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). The expansion will add a commercial-scale suite specifically designed for the development and manufacturing of payload-linkers, which is expected to be operational by the end of 2025.

The Lexington site is Piramal Pharma’s dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The expansion will add commercial-scale sterile injectable manufacturing capabilities with 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery, including a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. 

The expansion is expected to be completed by late 2027. Once completed, the Lexington site will double its manufacturing capacity and increase production batches per year.

Piramal Pharma recently broke ground on the Lexington site and held a ceremony. This represents an investment in the local community and creates 40 new full-time jobs. 

“As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements,” said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. “By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide.”